Symposia
2019 Programs
| New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia April 27, 2019 Houston, TX |
2018 Programs
| Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Castrate Resistant Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)
September 22, 2018 |
| 7th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia
June 23, 2018 |
Webcasts
2020 Webcasts
| Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma
Released on 12/30/19 |
| Changing Landscape of Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors
Released on 12/26/19 |
2019 Webcasts
| Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents
Released on 9/17/19 |
| Evolving Landscape of Treatment for Hepatocellular Carcinoma with Multi-Targeted Tyrosine Kinase Inhibitors and Immunotherapy
Released on 6/24/19 |
| Changing Landscape of Targeted and Immunotherapies for Genitourinary Cancers
Released on 6/12/19 |
| Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma with Anti-PD-1/PD-L1 Agents
Released on 6/10/19 |
| New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia
Released on 5/13/19 |
| Optimizing Outcomes in Patients with Malignant Melanoma Treated with Targeted Agents, Checkpoint Inhibitors and Oncolytic Viral Therapiesr
Released on 12/30/18 |
| Emerging Novel PI3K Inhibitors, Anti-CD20 mAb and Combination Therapy Options for Follicular Lymphoma
Released on 12/30/18 |
| Changing Landscape of Treatment Strategies of TKI Interruptions, Discontinuations and Switching in Patients with Chronic Myeloid Leukemia
Released on 12/30/18 |
| Update on Treatment Options for Acute Lymphoblastic Leukemia with An Emphasis on CD19, CD22 Monoclonal Antibodies and Anti-CD19 CAR T-cell Therapy
Released on 12/30/18 |